Sandu Pharmaceuticals share news, announcements and annual reports
BSE: 524703Pharmaceuticals & BiotechnologySmall Cap
Share price at the BSE close on 30 Oct 2026. Previous close ₹35.31.
30 Oct: open ₹35.56, high ₹36.40, low ₹35.01
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹35 Cr3,677th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 19.61
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 0.80
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 2.78%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 4.1%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 5.3%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.01
- Volume, BSEVolume. Shares traded on the last trading day. Volume in the glossary
- 2,591
Sandu Pharmaceuticals share news and announcements
659 announcements, routine notices left out, newest first. Page 9 of 14.
Apr 2020
Mar 2020
28 Mar · Business
25 Mar · Announcement under Regulation 30 (LODR)-Strikes /Lockouts / Disturbances
Feb 2020
14 Feb · Results
14 Feb · Board meeting
Jan 2020
15 Jan · Board meeting
Meeting on 14 Feb 2020: quarterly results11 Jan · Shareholding for the Period Ended December 31, 2019
Shareholding Pattern for the Period Ended December 31, 2019. For more details, kindly Click ....10 Jan · Statement Of Investor Complaints For The Quarter Ended December 2019
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0 1 1 09 Jan · Legal
8 Jan · Legal
Exchange has sought clarification from Sandu Pharmaceuticals Ltd on 08th January, 2020 with reference to significant movement in price, in order to ensure that investors have latest ....3 Jan · Intimation Under Regulation 30 Of SEBI (Listing Obligation And Disclosure Requirement)Regulation 2015.
Nov 2019
14 Nov · Results
14 Nov · Board meeting
Oct 2019
30 Oct · Board meeting
Meeting on 14 Nov 2019: quarterly results15 Oct · Statement Of Investor Complaints For The Quarter Ended September 2019
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0 2 2 011 Oct · Shareholding for the Period Ended September 30, 2019
Shareholding Pattern for the Period Ended September 30, 2019. For more details, kindly Click ....1 Oct · Results
Details of Voting results of AGM, under Regulation 44(3) of SEBI (LODR) Regulations, 2015. Kindly ....
Sep 2019
30 Sep · Meeting
3 Sep · Reg. 34 (1) Annual Report
Aug 2019
13 Aug · Board meeting
Jul 2019
31 Jul · Legal
Exchange has sought clarification from Sandu Pharmaceuticals Ltd on July 31, 2019 with reference to significant movement in price, in order to ensure that investors have latest relevant ....26 Jul · Board meeting
Meeting on 13 Aug 2019: quarterly results18 Jul · Shareholding for the Period Ended June 30, 2019
Shareholding Pattern for the Period Ended June 30, 2019. For more details, kindly Click ....13 Jul · Statement Of Investor Complaints For The Quarter Ended June 2019 (Revised)
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 1 3 4 013 Jul · Statement Of Investor Complaints For The Quarter Ended June 2019
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 1 0 1 0
Jun 2019
May 2019
29 May · Board meeting
29 May · Results
16 May · Board meeting
Meeting on 29 May 2019: audited results
Apr 2019
22 Apr · Compliances-Certificate under Reg. 54 (5) of SEBI (DP) Regulations, 1996